Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.634 CHF
−120.48 M CHF
122.95 M CHF
114.06 M
About Karyopharm Therapeutics Inc.
Sector
CEO
Richard A. Paulson
Headquarters
Newton
Website
Founded
2008
FIGI
BBG00LVDN9W0
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
KPTI4906769
Karyopharm Therapeutics Inc 3.0% 15-OCT-2025Yield to maturity
27.45%
Maturity date
Oct 15, 2025
KPTI5813817
Karyopharm Therapeutics Inc 6.0% 13-MAY-2029Yield to maturity
12.13%
Maturity date
May 13, 2029
Explore more bonds
Frequently Asked Questions
The current price of 25K is 0.645 CHF — it has decreased by −55.49% in the past 24 hours. Watch KARYOPHARM THERAPE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange KARYOPHARM THERAPE stocks are traded under the ticker 25K.
25K stock has risen by 0.16% compared to the previous week, the month change is a 0.16% rise, over the last year KARYOPHARM THERAPE has showed a −55.49% decrease.
We've gathered analysts' opinions on KARYOPHARM THERAPE future price: according to them, 25K price has a max estimate of 6.04 CHF and a min estimate of 1.73 CHF. Watch 25K chart and read a more detailed KARYOPHARM THERAPE stock forecast: see what analysts think of KARYOPHARM THERAPE and suggest that you do with its stocks.
25K stock is 125.00% volatile and has beta coefficient of 0.49. Track KARYOPHARM THERAPE stock price on the chart and check out the list of the most volatile stocks — is KARYOPHARM THERAPE there?
Today KARYOPHARM THERAPE has the market capitalization of 95.88 M, it has increased by 1.85% over the last week.
Yes, you can track KARYOPHARM THERAPE financials in yearly and quarterly reports right on TradingView.
KARYOPHARM THERAPE is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
25K earnings for the last quarter are −0.22 CHF per share, whereas the estimation was −0.22 CHF resulting in a 1.09% surprise. The estimated earnings for the next quarter are −0.22 CHF per share. See more details about KARYOPHARM THERAPE earnings.
KARYOPHARM THERAPE revenue for the last quarter amounts to 32.87 M CHF, despite the estimated figure of 32.14 M CHF. In the next quarter, revenue is expected to reach 33.33 M CHF.
25K net income for the last quarter is −27.18 M CHF, while the quarter before that showed 21.39 M CHF of net income which accounts for −227.06% change. Track more KARYOPHARM THERAPE financial stats to get the full picture.
No, 25K doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 325.00 employees. See our rating of the largest employees — is KARYOPHARM THERAPE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KARYOPHARM THERAPE EBITDA is −106.47 M CHF, and current EBITDA margin is −88.34%. See more stats in KARYOPHARM THERAPE financial statements.
Like other stocks, 25K shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KARYOPHARM THERAPE stock right from TradingView charts — choose your broker and connect to your account.